It's impossible to ignore the chatter about Ozempic, Wegovy, and other weight-loss medications that have hit the market in the last few years. This week, Hims & Hers -- a telehealth company known for discreetly treating erectile dysfunction, balding, and other sensitive conditions -- announced the launch of their own off brand weight-loss injection, sparking a boost in their stock prices. Melissa Lee, Host of CNBC's Fast Money, takes us into the marketplace for GLP-1 agonist drugs, Ozempic dupes sold online, and what the popularity of these drugs on Wall Street means for patients.